Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
Christine M. Lovly(Vanderbilt University), Nerina T. McDonald(Vanderbilt University), Heidi Chen(Vanderbilt University), Sandra Ortiz‐Cuaran(University Hospital Cologne), Lukas C. Heukamp(Integrated Oncology (United States)), Yingjun Yan(Vanderbilt University), Alexandra Florin(University Hospital Cologne), Luka Ozretić(University Hospital Cologne), Diana Lim(Memorial Sloan Kettering Cancer Center), Lu Wang(Memorial Sloan Kettering Cancer Center), Chen Zhao(Dana-Farber Cancer Institute), Xi Chen(Vanderbilt University), Lu Wang(Vanderbilt University), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Ronglai Shen(Memorial Sloan Kettering Cancer Center), Hailing Jin(Vanderbilt University), Reinhard Buettner(University Hospital Cologne), Sascha Ansén(University Hospital Cologne), Sven Perner, Michael Brockmann(Lungenklinik Köln-Merheim), Marc Bos(Integrated Oncology (United States)), Jürgen Wolf(University Hospital Cologne), Masyar Gardizi(University Hospital Cologne), Gavin Wright(The University of Melbourne), Benjamin Solomon(Peter MacCallum Cancer Centre), Prudence A. Russell(St Vincent's Hospital Melbourne), Toni-Maree Rogers(Peter MacCallum Cancer Centre), Yoshiyuki Suehara(Memorial Sloan Kettering Cancer Center), Monica Red-Brewer(Vanderbilt University), Rudy Tieu(Memorial Sloan Kettering Cancer Center), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center), Qingguo Wang(Vanderbilt University), Zhongming Zhao(Vanderbilt University), David H. Johnson(Baylor School), Leora Horn(Vanderbilt University), Kwok‐Kin Wong(Dana-Farber Cancer Institute), Roman K. Thomas(Integrated Oncology (United States)), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), William Pao(Vanderbilt University)
Cited by 267Open Access